Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Alternative therapies for menopausal women].
von Hagens C, Reinhard-Hennch B, Strowitzki T. von Hagens C, et al. MMW Fortschr Med. 2008 Oct 23;150(43):29-32. MMW Fortschr Med. 2008. PMID: 19031581 German. No abstract available.
[Complementary and alternative therapies for climacteric symptoms].
Reinhard-Hennch B, Strowitzki T, von Hagens C. Reinhard-Hennch B, et al. Among authors: von hagens c. Gynakol Geburtshilfliche Rundsch. 2006;46(4):197-213. doi: 10.1159/000095728. Gynakol Geburtshilfliche Rundsch. 2006. PMID: 17068404 Review. German.
Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2).
von Hagens C, Walter-Sack I, Goeckenjan M, Osburg J, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Edler L, Munzinger J, Efferth T, Schneeweiss A, Strowitzki T. von Hagens C, et al. Breast Cancer Res Treat. 2017 Jul;164(2):359-369. doi: 10.1007/s10549-017-4261-1. Epub 2017 Apr 24. Breast Cancer Res Treat. 2017. PMID: 28439738 Clinical Trial.
Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).
von Hagens C, Walter-Sack I, Goeckenjan M, Storch-Hagenlocher B, Sertel S, Elsässer M, Remppis BA, Munzinger J, Edler L, Efferth T, Schneeweiss A, Strowitzki T. von Hagens C, et al. Phytomedicine. 2019 Feb 15;54:140-148. doi: 10.1016/j.phymed.2018.09.178. Epub 2018 Sep 17. Phytomedicine. 2019. PMID: 30668363 Clinical Trial.
Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S. König M, et al. Among authors: von hagens c. Cancer Chemother Pharmacol. 2016 Feb;77(2):413-27. doi: 10.1007/s00280-016-2960-7. Epub 2016 Jan 21. Cancer Chemother Pharmacol. 2016. PMID: 26793976 Clinical Trial.
Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study.
König M, von Hagens C, Hoth S, Baumann I, Walter-Sack I, Edler L, Sertel S. König M, et al. Among authors: von hagens c. Cancer Chemother Pharmacol. 2016 Jun;77(6):1321. doi: 10.1007/s00280-016-3023-9. Cancer Chemother Pharmacol. 2016. PMID: 27094900 No abstract available.
18 results